ClinicalTrials.gg
CompletedNCT02951195Updated Jan 28, 2021Results posted

A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis

A Phase 2 interventional study of VX-152 and TEZ/IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-28.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing tezacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. tezacaftor · Cystic Fibrosis.

Enrollment
28th of 43
80 · median 100
Started
2016
with 5 others
Phase 2
8 of 43
none open now
Registered
12th of 43
by date
Lead sponsor
39 of 43
Vertex Pharmaceuticals Incorporated

Among the 43 studies testing tezacaftor in Cystic Fibrosis, this one is the 28th largest by enrollment, is one of 6 that started in 2016, is one of 8 in phase 2, and was the 12th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

4 of the 43 studies testing tezacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About tezacaftor

tezacaftor: first FDA approval 2024 (ALYFTREK), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tezacaftor in Cystic Fibrosis, or all of them as a file.
02

Study summary

This is a Phase 2, randomized, double blind, placebo and active-controlled, parallel group, multicenter study designed to evaluate the safety and tolerability of VX-152 in Triple Combination (TC) with tezacaftor (TEZ; VX-661) and ivacaftor (IVA; VX-770) in subjects with cystic fibrosis (CF) who are heterozygous for the F508del mutation and a minimal function (MF) CFTR mutation not likely to respond to TEZ and/or IVA therapy (F508del/MF), or who are homozygous for the F508del mutation of the CF transmembrane conductance regulator (CFTR) gene (F508del/F508del).

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to comply with scheduled visits, treatment pan, study restrictions, laboratory tests, guidelines, and other study procedures.
  • Body weight ≥35 kg.
  • Sweat chloride value ≥ 60 mmol/L from test results obtained during screening.
  • Subjects must have an eligible CFTR genotype:

    • Cohorts 1A, 1B, 1C: Heterozygous for F508del and a minimal function mutation known or predicted not to respond to TEZ and/or IVA.
    • Cohorts 2A, 2B: Homozygous for F508del.
  • Subjects must have an ≥40% and ≤90% of predicted normal for age, sex, and height at the Screening Visit.
  • Stable CF disease as judged by the investigator.
  • Willing to remain on a stable CF medication regimen through the planned end of treatment or if applicable the Safety Follow-up Visit.

Exclusion criteria

Exclusion Criteria:

  • History of any comorbidity that in the opinion of the investigator might confound the results of the study or pose an additional risk in administering study drug to the subject.
  • History of cirrhosis with portal hypertension.
  • Risk factors for Torsade de Pointes.
  • History of hemolysis.
  • Glucose-6-phosphate dehydrogenase (G6PD) deficiency assessed at Screening.
  • abnormal laboratory values at screening.
  • An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy for pulmonary disease within 28 days before the first dose of study drug.
  • Lung infection with organisms associated with a more rapid decline in pulmonary status.
  • An acute illness not related to CF within 14 days before the first dose of study drug.
  • A standard digital demonstrating >450 msec at screening.
  • History of solid organ or hematological transplantation.
  • History or evidence of cataract or lens opacity determined to be clinically significant by the ophthalmologist or optometrist, based on the ophthalmologic examination during the Screening Period.
  • History of alcohol or drug abuse in the past year, including but not limited to, cannabis, cocaine, and opiates, as deemed by the investigator.
  • Ongoing or prior participation in an drug study with certain exceptions.
  • Use of commercially available CFTR modulator within 14 days before screening (applies only to Cohorts 1A, 1B, and 1C).
  • Pregnant or nursing females: Females of must have a negative pregnancy test at screening and Day 1.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
80 participants (actual)

Study arms

  • Placebo comparator
    Part 1: Placebo

    Drug: Placebo

  • Experimental
    Part 1 Cohort 1A: TC

    Drug: VX-152 · Drug: TEZ/IVA · Drug: IVA

  • Experimental
    Part 1 Cohort 1B: TC

    Drug: VX-152 · Drug: TEZ/IVA · Drug: IVA

  • Experimental
    Part 1 Cohort 1C: TC

    Drug: VX-152 · Drug: TEZ/IVA · Drug: IVA

  • Active comparator
    Part 2 Cohort 2A: TEZ/IVA

    Drug: TEZ/IVA · Drug: IVA · Drug: Placebo

  • Experimental
    Part 2 Cohort 2A: TC

    Drug: VX-152 · Drug: TEZ/IVA · Drug: IVA

  • Active comparator
    Part 2 Cohort 2B: TEZ/IVA

    Drug: TEZ/IVA · Drug: IVA · Drug: Placebo

  • Experimental
    Part 2 Cohort 2B: TC

    Drug: VX-152 · Drug: TEZ/IVA · Drug: IVA

Interventions

  • DrugVX-152

    Tablet for oral administration.

  • DrugTEZ/IVA

    Drug pages: Tezacaftor · Ivacaftor

    Fixed-dose combination tablet for oral administration.

    Also known as: VX-661/VX-770, Tezacaftor/Ivacaftor

  • DrugIVA

    Tablet for oral administration.

    Also known as: VX-770, Ivacaftor

  • DrugPlacebo

    Placebo matched to VX-152.

  • DrugPlacebo

    Placebo matched to VX-152/TEZ/IVA triple combination (TC).

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Day 1 Through Safety Follow-up Visit (Up to Day 43 for Part 1 and Day 71 for Part 2)

  2. Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 15 for Part 1 and Part 2 Cohort 2A

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

    Time frame: From Baseline at Day 15

  3. Absolute Change in ppFEV1 Through Day 29 for Part 2 Cohort 2B

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

    Time frame: From Baseline Through Day 29

Secondary outcomes

  1. Absolute Change in Sweat Chloride Concentrations at Day 15 for Part 1 and Part 2 Cohort 2A

    Sweat samples were collected using an approved collection device.

    Time frame: From Baseline at Day 15

  2. Absolute Change in Sweat Chloride Concentrations Through Day 29 for Part 2 Cohort 2B

    Sweat samples were collected using an approved collection device.

    Time frame: From Baseline Through Day 29

  3. Relative Change in ppFEV1 at Day 15 for Part 1 and Part 2 Cohort 2A

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

    Time frame: From Baseline at Day 15

  4. Relative Change in ppFEV1 Through Day 29 for Part 2 Cohort 2B

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

    Time frame: From Baseline Through Day 29

  5. Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Day 15 for Part 1 and Part 2 Cohort 2A

    The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

    Time frame: From Baseline at Day 15

  6. Absolute Change From Baseline in CFQ-R Respiratory Domain Score at Day 29 for Part 2 Cohort 2B

    The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

    Time frame: From Baseline at Day 29

  7. Pre-dose Plasma Concentration (Ctrough) of VX-152, TEZ, M1-TEZ, IVA, and M1-IVA

    Time frame: Pre-dose at Day 8, Day 15 and Day 29

07

Results

Posted Jan 28, 2021

Participant flow

Participant flow — Overall Study
MilestonePart 1: PlaceboPart 1 Cohort 1A: TCPart 1 Cohort 1B: TCPart 1 Cohort 1C: TCPart 2 Cohort 2A: TEZ/IVAPart 2 Cohort 2A: TCPart 2 Cohort 2B: TEZ/IVAPart 2 Cohort 2B: TC
Started861010410721
Completed861010410721
Not completed00000000

Outcome measures

PrimarySafety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame:
Day 1 Through Safety Follow-up Visit (Up to Day 43 for Part 1 and Day 71 for Part 2)
Reported as:
Number · participants
Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
participantsPart 1: PlaceboPart 1 Cohort 1A: TCPart 1 Cohort 1B: TCPart 1 Cohort 1C: TCPart 2 Cohort 2A: TEZ/IVAPart 2 Cohort 2A: TCPart 2 Cohort 2B: TEZ/IVAPart 2 Cohort 2B: TC
Participants with TEAEs8371036519
Participants with SAEs20010000
PrimaryAbsolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 15 for Part 1 and Part 2 Cohort 2A

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame:
From Baseline at Day 15
Reported as:
Least squares mean · percentage points
Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 15 for Part 1 and Part 2 Cohort 2A
percentage pointsPart 1: PlaceboPart 1 Cohort 1A: TCPart 1 Cohort 1B: TCPart 1 Cohort 1C: TCPart 2 Cohort 2A: TEZ/IVAPart 2 Cohort 2A: TC
Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 15 for Part 1 and Part 2 Cohort 2A-0.8 (-4.8 to 3.3)5.7 (1.0 to 10.3)9.7 (6.1 to 13.3)8.0 (4.0 to 12.0)-1.0 (-9.9 to 7.8)7.3 (1.9 to 12.6)
Statistical analysis
  • Part 1: Placebo vs Part 1 Cohort 1A: TC · Mixed-effects Model for Repeated Measure · p = 0.0207 · Ls mean difference: 6.4 · 95% CI 0.3 to 12.6
  • Part 1: Placebo vs Part 1 Cohort 1B: TC · Mixed-effects Model for Repeated Measure · p = 0.0002 · Ls mean difference: 10.5 · 95% CI 5.0 to 15.9
  • Part 1: Placebo vs Part 1 Cohort 1C: TC · Mixed-effects Model for Repeated Measure · p = 0.0019 · Ls mean difference: 8.8 · 95% CI 3.0 to 14.5
  • Part 2 Cohort 2A: TEZ/IVA vs Part 2 Cohort 2A: TC · Mixed-effects Model for Repeated Measure · p = 0.0540 · Ls mean difference: 8.3 · 95% CI -2.1 to 18.7
PrimaryAbsolute Change in ppFEV1 Through Day 29 for Part 2 Cohort 2B

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame:
From Baseline Through Day 29
Reported as:
Least squares mean · percentage points
Absolute Change in ppFEV1 Through Day 29 for Part 2 Cohort 2B
percentage pointsPart 2 Cohort 2B: TEZ/IVAPart 2 Cohort 2B: TC
Absolute Change in ppFEV1 Through Day 29 for Part 2 Cohort 2B-2.2 (-6.6 to 2.1)6.5 (4.0 to 9.0)
Statistical analysis
  • Part 2 Cohort 2B: TEZ/IVA vs Part 2 Cohort 2B: TC · Mixed-effects Model for Repeated Measure · p = 0.0007 · Ls mean difference: 8.7 · 95% CI 3.7 to 13.8
SecondaryAbsolute Change in Sweat Chloride Concentrations at Day 15 for Part 1 and Part 2 Cohort 2A

Sweat samples were collected using an approved collection device.

Time frame:
From Baseline at Day 15
Reported as:
Least squares mean · millimole per liter (mmol/L)
Absolute Change in Sweat Chloride Concentrations at Day 15 for Part 1 and Part 2 Cohort 2A
millimole per liter (mmol/L)Part 1: PlaceboPart 1 Cohort 1A: TCPart 1 Cohort 1B: TCPart 1 Cohort 1C: TCPart 2 Cohort 2A: TEZ/IVAPart 2 Cohort 2A: TC
Absolute Change in Sweat Chloride Concentrations at Day 15 for Part 1 and Part 2 Cohort 2A-0.1 (-8.4 to 8.3)-19.5 (-29.1 to -10.0)-13.6 (-21.4 to -5.8)-27.5 (-35.0 to -20.1)3.5 (-9.2 to 16.2)-21.3 (-29.5 to -13.1)
Statistical analysis
  • Part 1: Placebo vs Part 1 Cohort 1A: TC · Mixed-effects Model for Repeated Measure · p = 0.0018 · Least squares (ls) mean difference: -19.5 · 95% CI -32.2 to -6.8
  • Part 1: Placebo vs Part 1 Cohort 1B: TC · Mixed-effects Model for Repeated Measure · p = 0.0106 · Ls mean difference: -13.6 · 95% CI -25.0 to -2.1
  • Part 1: Placebo vs Part 1 Cohort 1C: TC · Mixed-effects Model for Repeated Measure · p = <0.0001 · Ls mean difference: -27.5 · 95% CI -38.6 to -16.3
  • Part 2 Cohort 2A: TEZ/IVA vs Part 2 Cohort 2A: TC · Mixed-effects Model for Repeated Measure · p = 0.0017 · Ls mean difference: -24.8 · 95% CI -40.0 to -9.7
SecondaryAbsolute Change in Sweat Chloride Concentrations Through Day 29 for Part 2 Cohort 2B

Sweat samples were collected using an approved collection device.

Time frame:
From Baseline Through Day 29
Reported as:
Least squares mean · mmol/L
Absolute Change in Sweat Chloride Concentrations Through Day 29 for Part 2 Cohort 2B
mmol/LPart 2 Cohort 2B: TEZ/IVAPart 2 Cohort 2B: TC
Absolute Change in Sweat Chloride Concentrations Through Day 29 for Part 2 Cohort 2B1.6 (-6.8 to 10.0)-22.3 (-27.3 to -17.3)
Statistical analysis
  • Part 2 Cohort 2B: TEZ/IVA vs Part 2 Cohort 2B: TC · Mixed-effects Model for Repeated Measure · p = <0.0001 · Ls mean difference: -23.9 · 95% CI -33.7 to -14.1
SecondaryRelative Change in ppFEV1 at Day 15 for Part 1 and Part 2 Cohort 2A

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame:
From Baseline at Day 15
Reported as:
Least squares mean · percent change
Relative Change in ppFEV1 at Day 15 for Part 1 and Part 2 Cohort 2A
percent changePart 1: PlaceboPart 1 Cohort 1A: TCPart 1 Cohort 1B: TCPart 1 Cohort 1C: TCPart 2 Cohort 2A: TEZ/IVAPart 2 Cohort 2A: TC
Relative Change in ppFEV1 at Day 15 for Part 1 and Part 2 Cohort 2A-2.3 (-9.8 to 5.3)10.3 (1.6 to 19.0)19.0 (12.3 to 25.8)14.8 (7.3 to 22.4)-1.4 (-17.1 to 14.4)13.2 (3.7 to 22.7)
Statistical analysis
  • Part 1: Placebo vs Part 1 Cohort 1A: TC · Mixed-effects Model for Repeated Measure · p = 0.0166 · Ls mean difference: 12.5 · 95% CI 1.1 to 24.0
  • Part 1: Placebo vs Part 1 Cohort 1B: TC · Mixed-effects Model for Repeated Measure · p = <0.0001 · Ls mean difference: 21.3 · 95% CI 11.2 to 31.4
  • Part 1: Placebo vs Part 1 Cohort 1C: TC · Mixed-effects Model for Repeated Measure · p = 0.0013 · Ls mean difference: 17.1 · 95% CI 6.3 to 27.8
  • Part 2 Cohort 2A: TEZ/IVA vs Part 2 Cohort 2A: TC · Mixed-effects Model for Repeated Measure · p = 0.0563 · Ls mean difference: 14.5 · 95% CI -3.8 to 32.9
SecondaryRelative Change in ppFEV1 Through Day 29 for Part 2 Cohort 2B

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame:
From Baseline Through Day 29
Reported as:
Least squares mean · percent change
Relative Change in ppFEV1 Through Day 29 for Part 2 Cohort 2B
percent changePart 2 Cohort 2B: TEZ/IVAPart 2 Cohort 2B: TC
Relative Change in ppFEV1 Through Day 29 for Part 2 Cohort 2B-2.0 (-9.2 to 5.1)11.5 (7.4 to 15.7)
Statistical analysis
  • Part 2 Cohort 2B: TEZ/IVA vs Part 2 Cohort 2B: TC · Mixed-effects Model for Repeated Measure · p = 0.0012 · Ls mean difference: 13.6 · 95% CI 5.3 to 21.9
SecondaryAbsolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Day 15 for Part 1 and Part 2 Cohort 2A

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

Time frame:
From Baseline at Day 15
Reported as:
Least squares mean · units on a scale
Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Day 15 for Part 1 and Part 2 Cohort 2A
units on a scalePart 1: PlaceboPart 1 Cohort 1A: TCPart 1 Cohort 1B: TCPart 1 Cohort 1C: TCPart 2 Cohort 2A: TEZ/IVAPart 2 Cohort 2A: TC
Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Day 15 for Part 1 and Part 2 Cohort 2A-7.6 (-18.6 to 3.4)6.6 (-6.0 to 19.1)21.8 (12.1 to 31.6)18.6 (8.8 to 28.5)5.8 (-8.0 to 19.6)10.6 (1.9 to 19.2)
Statistical analysis
  • Part 1: Placebo vs Part 1 Cohort 1A: TC · ANCOVA · p = 0.0476 · Ls mean difference: 14.1 · 95% CI -2.6 to 30.9
  • Part 1: Placebo vs Part 1 Cohort 1B: TC · ANCOVA · p = 0.0001 · Ls mean difference: 29.4 · 95% CI 14.8 to 44.0
  • Part 1: Placebo vs Part 1 Cohort 1C: TC · ANCOVA · p = 0.0006 · Ls mean difference: 26.2 · 95% CI 11.3 to 41.1
  • Part 2 Cohort 2A: TEZ/IVA vs Part 2 Cohort 2A: TC · Mixed-effects Model for Repeated Measure · p = 0.2714 · Ls mean difference: 4.8 · 95% CI -11.6 to 21.2
SecondaryAbsolute Change From Baseline in CFQ-R Respiratory Domain Score at Day 29 for Part 2 Cohort 2B

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

Time frame:
From Baseline at Day 29
Reported as:
Least squares mean · units on a scale
Absolute Change From Baseline in CFQ-R Respiratory Domain Score at Day 29 for Part 2 Cohort 2B
units on a scalePart 2 Cohort 2B: TEZ/IVAPart 2 Cohort 2B: TC
Absolute Change From Baseline in CFQ-R Respiratory Domain Score at Day 29 for Part 2 Cohort 2B4.8 (-3.7 to 13.3)16.1 (11.2 to 21.0)
Statistical analysis
  • Part 2 Cohort 2B: TEZ/IVA vs Part 2 Cohort 2B: TC · Mixed-effects Model for Repeated Measure · p = 0.0138 · Ls mean difference: 11.3 · 95% CI 1.3 to 21.2
SecondaryPre-dose Plasma Concentration (Ctrough) of VX-152, TEZ, M1-TEZ, IVA, and M1-IVA
Time frame:
Pre-dose at Day 8, Day 15 and Day 29
Reported as:
Mean · nanogram per milliliter (ng/mL)
Pre-dose Plasma Concentration (Ctrough) of VX-152, TEZ, M1-TEZ, IVA, and M1-IVA
nanogram per milliliter (ng/mL)Part 1 Cohort 1A: TCPart 1 Cohort 1B: TCPart 1 Cohort 1C: TCPart 2 Cohort 2A: TEZ/IVAPart 2 Cohort 2A: TCPart 2 Cohort 2B: TEZ/IVAPart 2 Cohort 2B: TC
Day 8: VX-152167 ± 65.4240 ± 370538 ± 576—355 ± 287—463 ± 730
Day 15: VX-152173 ± 72.1278 ± 212804 ± 812—554 ± 429—560 ± 657
Day 29: VX-152——————698 ± 1040
Day 8: TEZ2610 ± 14001500 ± 11401680 ± 9961900 ± 17301830 ± 6932010 ± 6691460 ± 1470
Day 15: TEZ2450 ± 20001220 ± 5451180 ± 4951120 ± 1351620 ± 10301970 ± 10401050 ± 543
Day 29: TEZ—————2470 ± 10601190 ± 422
Day 8: M1-TEZ4520 ± 10903060 ± 14803490 ± 16403760 ± 11004900 ± 10504980 ± 14504150 ± 1280
Day 15: M1-TEZ4680 ± 10202890 ± 8983310 ± 12203430 ± 8244270 ± 12804420 ± 18103650 ± 1320
Day 29: M1-TEZ—————4280 ± 16503680 ± 742
Day 8: IVA779 ± 442522 ± 401545 ± 234702 ± 425610 ± 262953 ± 360434 ± 251
Day 15: IVA841 ± 588535 ± 310467 ± 236441 ± 300645 ± 373863 ± 488389 ± 222
Day 29: IVA—————1010 ± 446468 ± 279
Day 8: M1-IVA1590 ± 10501040 ± 9471330 ± 7471660 ± 12001470 ± 6711810 ± 6651170 ± 551
Day 15: M1-IVA1230 ± 3261200 ± 8481140 ± 5501030 ± 7621510 ± 8911620 ± 7601100 ± 598
Day 29: M1-IVA—————1890 ± 6591240 ± 705

Adverse events

Collected over Day 1 Through Safety Follow-up Visit (Up to Day 43 for Part 1 and Day 71 for Part 2). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Placebo0/8 (0%)2/8 (25%)8/8 (100%)
Part 1 Cohort 1A: TC0/6 (0%)0/6 (0%)3/6 (50%)
Part 1 Cohort 1B: TC0/10 (0%)0/10 (0%)7/10 (70%)
Part 1 Cohort 1C: TC0/10 (0%)1/10 (10%)9/10 (90%)
Part 2 Cohort 2A: TEZ/IVA0/4 (0%)0/4 (0%)3/4 (75%)
Part 2 Cohort 2A: TC0/10 (0%)0/10 (0%)6/10 (60%)
Part 2 Cohort 2B: TEZ/IVA0/7 (0%)0/7 (0%)5/7 (71.4%)
Part 2 Cohort 2B: TC0/21 (0%)0/21 (0%)18/21 (85.7%)
Most frequent serious events
Most frequent serious events
EventPart 1: PlaceboPart 1 Cohort 1A: TCPart 1 Cohort 1B: TCPart 1 Cohort 1C: TCPart 2 Cohort 2A: TEZ/IVAPart 2 Cohort 2A: TCPart 2 Cohort 2B: TEZ/IVAPart 2 Cohort 2B: TC
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations1/80/60/101/100/40/100/70/21
Viral infectionInfections and infestations1/80/60/100/100/40/100/70/21
Most frequent other events
Showing 10 of 79
Most frequent other events
EventPart 1: PlaceboPart 1 Cohort 1A: TCPart 1 Cohort 1B: TCPart 1 Cohort 1C: TCPart 2 Cohort 2A: TEZ/IVAPart 2 Cohort 2A: TCPart 2 Cohort 2B: TEZ/IVAPart 2 Cohort 2B: TC
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations3/80/61/100/100/41/103/75/21
DiarrhoeaGastrointestinal disorders0/82/62/101/100/40/100/73/21
Productive coughRespiratory, thoracic and mediastinal disorders0/82/62/102/100/40/100/73/21
HeadacheNervous system disorders0/81/61/103/101/40/100/74/21
CoughRespiratory, thoracic and mediastinal disorders1/80/63/101/101/41/100/76/21
Sputum increasedRespiratory, thoracic and mediastinal disorders1/81/62/101/100/41/101/76/21
NauseaGastrointestinal disorders1/80/60/100/101/40/100/72/21
GastroenteritisInfections and infestations0/80/60/100/101/40/100/70/21
Muscle strainInjury, poisoning and procedural complications0/80/60/100/101/40/100/70/21
Weight decreasedInvestigations0/80/60/100/101/40/100/70/21

Baseline characteristics

Age, Customized
Age, Customized(Participants)Part 1: PlaceboPart 1 Cohort 1A: TCPart 1 Cohort 1B: TCPart 1 Cohort 1C: TCPart 2 Cohort 2A: TEZ/IVAPart 2 Cohort 2A: TCPart 2 Cohort 2B: TEZ/IVAPart 2 Cohort 2B: TCTotal
<18 years000000000
>=18 and <65 years86101041072176
>=65 years000000000
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: PlaceboPart 1 Cohort 1A: TCPart 1 Cohort 1B: TCPart 1 Cohort 1C: TCPart 2 Cohort 2A: TEZ/IVAPart 2 Cohort 2A: TCPart 2 Cohort 2B: TEZ/IVAPart 2 Cohort 2B: TCTotal
Female42432641439
Male4467243737
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: PlaceboPart 1 Cohort 1A: TCPart 1 Cohort 1B: TCPart 1 Cohort 1C: TCPart 2 Cohort 2A: TEZ/IVAPart 2 Cohort 2A: TCPart 2 Cohort 2B: TEZ/IVAPart 2 Cohort 2B: TCTotal
Hispanic or Latino200100003
Not Hispanic or Latino6610941072173
Unknown or Not Reported000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: PlaceboPart 1 Cohort 1A: TCPart 1 Cohort 1B: TCPart 1 Cohort 1C: TCPart 2 Cohort 2A: TEZ/IVAPart 2 Cohort 2A: TCPart 2 Cohort 2B: TEZ/IVAPart 2 Cohort 2B: TCTotal
American Indian or Alaska Native000000000
Asian000000000
Native Hawaiian or Other Pacific Islander000000000
Black or African American000000000
White75101041072174
More than one race000000000
Unknown or Not Reported110000002
Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)(Participants)Part 1: PlaceboPart 1 Cohort 1A: TCPart 1 Cohort 1B: TCPart 1 Cohort 1C: TCPart 2 Cohort 2A: TEZ/IVAPart 2 Cohort 2A: TCPart 2 Cohort 2B: TEZ/IVAPart 2 Cohort 2B: TCTotal
<40 percent102100004
≥40 to <70 percent567431051858
≥70 to ≤90 percent2015102314
>90 percent000000000
08

Study locations

16 sites
  • Birmingham, Alabama, United States
  • La Jolla, California, United States
  • Los Angeles, California, United States
  • Orlando, Florida, United States
  • Chicago, Illinois, United States
  • Peoria, Illinois, United States
  • Saint Louis, Missouri, United States
  • Chapel Hill, North Carolina, United States
  • Akron, Ohio, United States
  • Cleveland, Ohio, United States
  • Portland, Oregon, United States
  • Philadelphia, Pennsylvania, United States
  • Charleston, South Carolina, United States
  • Fort Worth, Texas, United States
  • Houston, Texas, United States
  • Madison, Wisconsin, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Jan 2018, 14 months.

Results were first posted in Jan 2021, 3 years after primary completion. A results delay was requested in Jan 2019.

Of 40 industry-sponsored phase 2 interventional studies under Cystic Fibrosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's 14 months is close to that.

Counting every sponsor, half of 57 studies reached it within 21 months; a quarter within 9 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2016
First posted
Nov 1, 2016
StartActual
Nov 2016
Primary completionActual
Jan 2018
CompletionActual
Jan 2018
Results delay requested
Jan 9, 2019
Results first posted
Jan 28, 2021
Last update
Jan 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02951195
Responsible party
Sponsor
First posted
Nov 1, 2016
Start date
Nov 2016
Primary completion
Jan 2018
Completion
Jan 2018
Results posted
Jan 28, 2021
Last update
Jan 28, 2021

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tezacaftor · Ivacaftor

Start the discussion